研究者業績
基本情報
- 所属
- 藤田医科大学 精神・神経病態解明センター 神経行動薬理学研究部門 教授(兼任)精神・神経病態解明センター 副センター長(兼任)大学院 医学研究科 神経行動薬理学 教授(兼任)オープンファシリティーセンター 副センター長
- 学位
- 修士(薬学)(名城大学)博士(医学)(名古屋大学)
- J-GLOBAL ID
- 200901083965882198
- researchmap会員ID
- 5000081871
研究分野
1経歴
5-
2020年1月 - 現在
-
2010年1月 - 2019年12月
-
2006年4月 - 2009年12月
-
2004年4月 - 2006年3月
-
2003年4月 - 2004年3月
委員歴
14-
2021年9月 - 現在
-
2019年3月 - 現在
-
2016年10月 - 現在
-
2016年10月 - 現在
-
2013年4月 - 2019年12月
受賞
10-
2017年9月
-
2015年10月
-
2013年7月
-
2012年10月
論文
187-
European Journal of Pharmacology 2026年1月
-
International Journal of Molecular Sciences 2025年5月28日
-
British Journal of Pharmacology 2024年12月10日Background and Purpose Alterations in tryptophan‐kynurenine (TRP‐KYN) pathway are implicated in major depressive disorder (MDD). α7 nicotinic acetylcholine (α7nACh) receptor regulates the hypothalamic–pituitary–adrenal (HPA) axis. We have shown that deficiency of kynurenine 3‐monooxygenase (KMO) induces depression‐like behaviour via kynurenic acid (KYNA; α7nACh antagonist). In this study, we investigated the involvement of the TRP‐KYN pathway in stress‐induced behavioural changes and the regulation of the HPA axis. Experimental Approach Mice were exposed to chronic unpredictable mild stress (CUMS) and subjected to behavioural tests. We measured TRP‐KYN metabolites and the expression of their enzymes in the hippocampus. KMO heterozygous mice were used to investigate stress vulnerability. We also evaluated the effect of nicotine (s.c.) on CUMS‐induced behavioural changes and an increase in serum corticosterone (CORT) concentration. Key Results CUMS decreased social interaction time but increased immobility time under tail suspension associated with increased serum corticosterone concentration. CUMS increased KYNA levels via KMO suppression with microglial decline in the hippocampus. Kmo+/− mice were vulnerable to stress: they exhibited social impairment and increased serum corticosterone concentration even after short‐term CUMS. Nicotine attenuated CUMS‐induced behavioural changes and increased serum corticosterone concentration by inhibiting the increase in corticotropin‐releasing hormone. Methyllycaconitine (α7nACh antagonist) inhibited the attenuating effect of nicotine. Conclusions and Implications CUMS‐induced behavioural changes and the HPA axis dysregulation could be induced by the increased levels of KYNA via KMO suppression. KYNA plays an important role in the pathophysiology of MDD as an α7nACh antagonist. Therefore, α7nACh receptor is an attractive therapeutic target for MDD.
-
Neuropsychopharmacology 2024年10月11日Abstract Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT1A receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635—a 5-HT1A receptor antagonist—antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT1A receptors in prenatal VPA mice.
-
Science signaling 17(853) eado9852 2024年9月10日Structural plasticity of dendritic spines in the nucleus accumbens (NAc) is crucial for learning from aversive experiences. Activation of NMDA receptors (NMDARs) stimulates Ca2+-dependent signaling that leads to changes in the actin cytoskeleton, mediated by the Rho family of GTPases, resulting in postsynaptic remodeling essential for learning. We investigated how phosphorylation events downstream of NMDAR activation drive the changes in synaptic morphology that underlie aversive learning. Large-scale phosphoproteomic analyses of protein kinase targets in mouse striatal/accumbal slices revealed that NMDAR activation resulted in the phosphorylation of 194 proteins, including RhoA regulators such as ARHGEF2 and ARHGAP21. Phosphorylation of ARHGEF2 by the Ca2+-dependent protein kinase CaMKII enhanced its RhoGEF activity, thereby activating RhoA and its downstream effector Rho-associated kinase (ROCK/Rho-kinase). Further phosphoproteomic analysis identified 221 ROCK targets, including the postsynaptic scaffolding protein SHANK3, which is crucial for its interaction with NMDARs and other postsynaptic scaffolding proteins. ROCK-mediated phosphorylation of SHANK3 in the NAc was essential for spine growth and aversive learning. These findings demonstrate that NMDAR activation initiates a phosphorylation cascade crucial for learning and memory.
MISC
242-
ONCOLOGY REPORTS 31(4) 1883-1890 2014年4月 査読有り
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 124 182P-182P 2014年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 124 47P-47P 2014年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 124 177P-177P 2014年
-
International Journal of Neuropsychopharmacology 17(5) 723-737 2014年 査読有り
-
Journal of neuroscience research 91(12) 1525-32 2013年12月 査読有りWe previously identified a new molecule, "SHATI/NAT8L," which has an inhibitory effect on methamphetamine (METH)-induced hyperlocomotion, sensitization, and conditioned place preference. Nevertheless, the extent of SHATI localization and its functions are only partially understood. In this study, we used the FLAG-tag method to investigate SHATI localization. We found that SHATI was localized to microtubules when expressed in COS7 cells and cortical primary neurons. This distribution of SHATI was less apparent after cells were treated with colchicine, a tubulin polymerization inhibitor that disrupts the microtubule structure. This finding suggests that SHATI is associated with microtubule structure. Interestingly, overexpression of SHATI in COS7 cells could attenuate the colchicine-induced decrease in acetylated microtubules, indicating that SHATI plays a role in stabilizing microtubules. Furthermore, we showed that Shati deletion impaired neurite elongation. In cortical primary neurons, neurite length and complexity in Shati-knockout (KO) mice were significantly decreased. In pyramidal neurons in the prefrontal cortex, dendrite length and complexity were also significantly decreased in Shati-KO mice compared with wild-type mice. These results suggest a novel function for SHATI, which may be a new member of the microtubule-associated protein family.
-
Japanese Journal of Neuropsychopharmacology 33(4) 149-154 2013年8月
-
Behavioural Brain Research 250 351-360 2013年8月1日 査読有り
-
GLIA 61(5) 679-693 2013年5月 査読有り
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 181P-181P 2013年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 176P-176P 2013年
-
Involvement of astroglial IFITM3 in neuronal impairments following neonatal immune challenge in miceJOURNAL OF PHARMACOLOGICAL SCIENCES 121 32P-32P 2013年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 212P-212P 2013年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 122P-122P 2013年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 64P-64P 2013年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 121 66P-66P 2013年 査読有り
-
Journal of Biological Chemistry 288(4) in press 2013年 査読有り
-
JOURNAL OF NEUROCHEMISTRY 123(5) 866-875 2012年12月 査読有り
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 120(3) 213-227 2012年11月 査読有り
-
JOURNAL OF NEUROCHEMISTRY 123 125-125 2012年10月
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 120(2) 89-97 2012年10月 査読有り
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 15 64-65 2012年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 15 164-164 2012年6月
-
NEUROPSYCHOPHARMACOLOGY 37(6) 1387-1396 2012年5月 査読有り
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 32(2) 87-89 2012年4月25日
-
NEUROSCIENCE 207 261-273 2012年4月 査読有り
-
MOLECULAR BIOLOGY OF THE CELL 23 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 29P-29P 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 109P-109P 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 67P-67P 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 231P-231P 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 227P-227P 2012年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 190P-190P 2012年
-
HUMAN MOLECULAR GENETICS 20(23) 4666-4683 2011年12月 査読有り
-
BEHAVIOURAL BRAIN RESEARCH 225(1) 305-310 2011年11月 査読有り
-
Behav. Brain Res. 225(1) 222-229 2011年11月 査読有り
-
Biological and Pharmaceutical Bulletin 34(9) 1364-1368 2011年9月 査読有り招待有り
書籍等出版物
1講演・口頭発表等
19担当経験のある科目(授業)
16-
2025年 - 現在
-
2025年 - 現在
-
2024年 - 現在
-
2023年 - 現在
-
2023年 - 現在
所属学協会
8共同研究・競争的資金等の研究課題
23-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
AMED 脳とこころの研究推進プログラム(精神・神経疾患メカニズム解明プロジェクト) 2021年 - 2024年
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2023年3月
産業財産権
1その他
1-
統合失調症マーカー及びその利用, 尾崎紀夫, 永井拓, 吉見陽, 山田真之亮.「国立大学法人名古屋大学, 特許番号6252949, 出願番号 特願 2014-542025, 管理番号 C20130185JP#P01, 出願日2013.10.3., 特許取得2017.12.8.